Skip to content
PreclinicalResearch compound

AC‑262 (AC‑262536, Accadrine)

Experimental SARM compound tested only in rats and cells, never in humans; today it is mostly studied so that doping controls can detect it.

Available at
DEUSPOWER logo
DEUSPOWERProduct page

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

AC-262 (AC-262536, Accadrine) vial

DETAILED OVERVIEW

What is AC-262 (AC-262536, Accadrine)?

AC-262 (AC-262536) is an experimental compound, a so-called SARM, or selective androgen receptor modulator: it attaches to the same docking site as testosterone. It was developed by ACADIA Pharmaceuticals, but development stopped at the experimental stage. It has not been approved as a medicine anywhere and is sold as a research chemical.

In rats it showed a muscle-building effect while stimulating the prostate less than testosterone does. It has never been tested in humans, so there are no data on its effects or safety; today's research mostly serves to detect it in doping control. For this group of compounds, a drop in the body's own testosterone production, lower HDL cholesterol and drug-induced liver injury are documented; for AC-262 these are only presumed, not measured. It must not be used in pregnancy, because it can cause masculinization of the baby. It is banned on the anti-doping list all year round.

What it is

Non-steroidal; partly activates the androgen receptor; developed by ACADIA

Evidence level

Preclinical. No human clinical trial has ever been conducted.

What Piu 2008 showed

Muscle anabolic effects in rats with less prostate stimulation.

Direction of current research

Doping analysis: metabolism and urinary detection.

Legal status

Not a medicine. WADA-banned year-round (S1.2).

Data console

Lab data

Androgenic:AnabolicThe Piu 2008 preclinical characterisation described muscle selectivity relative to the prostate, but no reliable ratio based on human data is available.
AR bindingA non-steroidal androgen receptor ligand characterised as…
Active half-lifehumánban nem meghatározott
Detection windowDetectable in urine by liquid chromatography-mass spectrometry; the method is described in Stacchini 2021. To be avoided by tested athletes.
AromatizationNO. AC-262 is non-steroidal, is not a substrate for aromatase and does not convert to estradiol.
HepatotoxicityUNKNOWN BUT PLAUSIBLE. There are no human hepatic safety data for AC-262. Within the SARM class, however, drug-induced liver injury is well documented (Solomon 2019), and structural kinship makes this a realistic risk for AC-262. "Unknown" here is not the same as "low".

Safety

Side effects, stop signs, contraindications

Side effects · 4

  • Unknown human profile: no human clinical trial exists, so the following are risks inferred from the androgen receptor modulator class rather than measured data.
  • HPTA suppression: androgen receptor activation reduces endogenous testosterone production; this is documented across the SARM class.
  • Risk of liver injury: SARM-associated drug-induced liver injury is well documented within the class (Solomon 2019).
  • Lipid deterioration: falling HDL cholesterol is a class effect of androgenic agents.

Contraindications · 4

  • Any human use without grounded clinical data: no human study has ever been conducted with AC-262, so there is no dose known to be safe.
  • Existing liver disease or elevated baseline ALT/AST.
  • Pregnancy and breastfeeding: androgen receptor activation can cause fetal virilization.
  • Competitive sport under testing: WADA bans SARMs year-round (S1.2), and a detection method covering AC-262 exists (Stacchini 2021).

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about AC‑262 (AC‑262536, Accadrine)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.